510(k) Summary

510(k) Summary		
Name of 510(k) Sponsor	Playtex Products, LLC	
1	6 Research Drive	
	Shelton, CT 06484	
	·	
Contact Information	Pushpa Rao, Ph.D., D.A.B.T., R.A.C.	
	Senior Manager, Product Safety/North American Regulatory Affairs	
	Research & Development	
	Playtex Products, LLC	
	75 Commerce Drive	
	Allendale, NJ 07401	
	Telephone: 201-785-8070	
	Facsimile: 201-785-8202	
	racsimile: 201-785-8202	
Summary prepared on	January 25, 2012	
Samuel Property of		
Pre-Market Notification #	·	
Reason for Submission	Changes to the applicator colorant, fragrance and pledget design	
	compared to predicate tampons. Pre-clinical and clinical testing	
	confirmed that these changes did not affect the safety of the modified	
!	tampon. These changes were not expected to affect efficacy, and this	
	was verified by performance testing. The results of these tests are	
·	included in this 510(k) pre-market notification.	
	included in this 310(k) pre-market notification.	
Name of Device		
Trade Name	Playtex® Gentle Glide Scented Tampons	
Trace Hame	Playtex® Gentle Glide Unscented Tampons	
	Trayton Contro Ondo Ondoontou Tumpons	
Common Name	Menstrual Tampon, Scented and Unscented	
Common Ivanie	Tanada Tanapan, Stanisa ana Omboditoa	
Classification Name	Tampon, Menstrual Scented and Unscented	
Classification Code	HIL, HEB	
Classification Code		
Predicate Devices	Playtex® Gentle Glide and Playtex® Gentle Glide Multipack Tampons	
	(K073662)	
	(**************************************	
	Playtex® Gentle Glide Plastic and Playtex® Gentle Glide Plastic	
1	1 = 1	
1	Multipack Tampons (K070745)	
·	Multipack Tampons (K070745)	
, .	Playtex® Non-deodorant Gentle Glide (unscented), Playtex Deodorant	
,	Playtex® Non-deodorant Gentle Glide (unscented), Playtex Deodorant Gentle Glide (Scented) and Playtex Non-deodorant and Deodorant	
	Playtex® Non-deodorant Gentle Glide (unscented), Playtex Deodorant	
Dovice Description	Playtex® Non-deodorant Gentle Glide (unscented), Playtex Deodorant Gentle Glide (Scented) and Playtex Non-deodorant and Deodorant Multipack Tampons (K072376)	
Device Description	Playtex® Non-deodorant Gentle Glide (unscented), Playtex Deodorant Gentle Glide (Scented) and Playtex Non-deodorant and Deodorant Multipack Tampons (K072376) Scented or scented deodorized, unscented menstrual tampons for the	
Device Description	Playtex® Non-deodorant Gentle Glide (unscented), Playtex Deodorant Gentle Glide (Scented) and Playtex Non-deodorant and Deodorant Multipack Tampons (K072376)	
-	Playtex® Non-deodorant Gentle Glide (unscented), Playtex Deodorant Gentle Glide (Scented) and Playtex Non-deodorant and Deodorant Multipack Tampons (K072376) Scented or scented deodorized, unscented menstrual tampons for the absorption of menstrual fluid.	
Device Description Intended Use	Playtex® Non-deodorant Gentle Glide (unscented), Playtex Deodorant Gentle Glide (Scented) and Playtex Non-deodorant and Deodorant Multipack Tampons (K072376) Scented or scented deodorized, unscented menstrual tampons for the	

	unscented menstrual tampons are inserted into the vagina and used to absorb menstrual fluid.
Technological Characteristics	The modified tampons have the same technological characteristics a predicate devices (K070745, K072376 and K073662). The fiber and materials in contact with the vaginal wall are the same or have the same of action. The only differences in the modified tampons from predicate tampons are: (1) the composition of the colorants incorpor into the polyethylene resin used to manufacture the applicator (barrel and plunger); (2) a new fragrance; (3) a new pledget design.
Biocompatibility Tests	Biocompatibility and microbiological studies of the modified tampo were conducted in accordance with the FDA guidance and applicabl standards. The results demonstrate that the modified Playtex Gentle Glide tampons are safe and effective for their intended use and are substantially equivalent to legally marketed predicate tampons. The testing included:
	Preclinical: Cytotoxicity Vaginal Irritation in Rabbits Acute Systemic Toxicity Zone of Inhibition (Vaginal Microflora) Toxic Shock Syndrome Test In vitro Vaginal Irritation
	Clinical Human Repeat Insult Patch Test (Sensitization) Human Vaginal Irritation (Safety In Use)
Performance Testing	Syngyna testing was conducted in accordance to 21 CFR §801.430(to verify that the modified tampons met absorbency ranges as spec in the regulation.
	 Absorbs menstrual flow < 6 grams (Slender Light) Absorbs menstrual flow 6-9 grams (Slender Regular, Regula Absorbs menstrual flow 9-12 grams (Super) Absorbs menstrual flow 12-15 grams (Super Plus) Absorbs menstrual flow 15-18 grams (Ultra)
	The tampons are labeled in accordance to these absorbency ranges.
Conclusion	The results of the preclinical and clinical testing indicate that the modified tampons are safe and effective for their intended use and we considered in conjunction with the performance testing results are substantially equivalent to the predicate devices.





Food and Drug Administration 10903 New Hampshire Avenue Document Control Room – WO66-G609 Silver Spring, MD 20993-0002

JUN 2 1 2012

Pushpa Rao, Ph.D., D.A.B.T, R.A.C. Senior Manager, Product Safety/North American Regulatory Affairs Playtex, Inc. 75 Commerce Drive ALLENDALE NJ 07401

Re: K120245

Trade/Device Name: Playtex® Gentle Glide Scented & Unscented Tampons

Regulation Number: 21 CFR§ 884.5460

Regulation Name: Scented or scented deodorized menstrual tampon

Regulatory Class: II Product Code: HIL, HEB Dated: June 11, 2012 Received: June 12, 2012

Dear Dr. Rao:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical

device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerély yours,

Benjamin R. Fisher, Ph.D.

Director

Division of Reproductive, Gastro-Renal, and Urological Devices

Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

Indications for Use

510(k) Number (if known	1):
Device Name:	
Playtex® Gentle Glide Scente	ed Tampons
Playtex® Gentle Glide Unsce	ented Tampons
Indications For Use:	
to absorb menstrual fluid.	ed menstrual tampons are intended to be inserted into the vagina and used ented menstrual tampons are intended to be inserted into the vagina and
used to absorb menstrual flui	
Absorbency Ranges:	Absorbs menstrual flow < 6 grams (Slender Light)
•	Absorbs menstrual flow 6-9 grams (Slender Regular, Regular)
	Absorbs menstrual flow 9-12 grams (Super)
	Absorbs menstrual flow 12-15 grams (Super Plus)
	Absorbs menstrual flow 15-18 grams (Ultra)
	•
٠	
•	
·	
Prescription Use(Part 21 CFR 801 Subpart	Over-The-Counter Use X (21 CFR 801 Subpart C)
	TE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF
	CORPH (CC CD in F. 1 din (ODE)
- L/I // Goncunte	nee of CDRH, Office of Device Evaluation (ODE)

510(k) Number